BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $32.00.

A number of research analysts have commented on the stock. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th.

Insider Buying and Selling

In other BioLife Solutions news, insider Karen A. Foster sold 96,923 shares of BioLife Solutions stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total value of $1,952,998.45. Following the transaction, the insider directly owned 113,742 shares in the company, valued at approximately $2,291,901.30. The trade was a 46.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 99,641 shares of company stock valued at $2,009,000 in the last quarter. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BLFS. Jacobs Levy Equity Management Inc. acquired a new position in shares of BioLife Solutions during the first quarter worth about $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of BioLife Solutions by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock worth $489,000 after acquiring an additional 914 shares during the period. Jane Street Group LLC acquired a new position in shares of BioLife Solutions during the first quarter worth about $1,091,000. Strs Ohio acquired a new position in shares of BioLife Solutions during the first quarter worth about $153,000. Finally, Qube Research & Technologies Ltd increased its stake in shares of BioLife Solutions by 2,399.5% during the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock worth $5,352,000 after acquiring an additional 238,533 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Price Performance

Shares of BLFS opened at $21.23 on Friday. BioLife Solutions has a 1-year low of $17.86 and a 1-year high of $29.62. The stock has a market cap of $1.04 billion, a PE ratio of -265.34 and a beta of 1.97. The firm has a fifty day moving average price of $20.28 and a 200 day moving average price of $23.22.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The firm had revenue of $27.50 million during the quarter, compared to analysts’ expectations of $25.66 million. As a group, equities analysts expect that BioLife Solutions will post 0.09 EPS for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.